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 In 1997, twenty one percent of the households in 
America chose to buy grapefruit juice to drink as their 
breakfast beverage. In recent years, the public have real-
ized the importance of including antioxidants in their diets, 
and the choice of grapefruit juice, which contains those 
compounds, reflects that awareness. Several chronic dis-
eases, most importantly cardiovascular disease and some 
cancers, could possibly be prevented by flavenoids and 
other components of grapefruit juice. Additionally, there 
was a study that was done that showed that grapefruit and 
grapefruit juice might promote weight loss (Mertens-
Talcott, et. al. 2006). Due to its possible health benefits, it’s 
hard for many people to believe that grapefruit juice can 
have an adverse effect when taken together with many 
common medications. 
 A drug interaction is a name given to the effect 
that any substance can have when ingested together with 
a medication. The possible effects fall into two categories: 
pharmacokinetics and pharmacodynamics. Pharmacoki-
netics includes changes in absorption, distribution, metab-
olism, and excretion. Pharmacodynamics is the description 
of the relationship between the concentration of the drug 
and its effect (Mertens-Talcott, et. al. 2006). Grapefruit 
juice causes pharmacokinetic interactions. When taken 
together with grapefruit juice, many medications display 
an increased bioavailability (Fuhr, 1998). This leads to un-
desired effects, such as decreased efficiacy or toxicity. In-
creased side effects can occur as well (Mertens-Talcott, et. 
al. 2006). The unpleasantness of toxicity can cause patients 
to stop taking the drugs, and in extreme cases, toxicity can 
even cause death (Bailey, Dresser, 2004). 
 The phenomenon of the grapefruit juice- drug in-
teraction was discovered by chance in 1989. An experi-
ment was being done to determine if there was an interac-
tion between felodipine, a calcium channel antagonist, and 
ethanol. Grapefruit juice was used to mask the taste of the 
ethanol. When the results were analyzed, it was discov-
ered that the concentrations of felodipine were significant-
ly higher than those recorded in other experiments, and 
the subjects had lower blood pressure and higher instanc-
es of unwanted side effects. Further testing was per-
formed to try to discover the cause, and it was found that 
the increased concentration was a result of the grapefruit 
juice. Since then, numerous drugs have been tested, and 
many have been found to interact with grapefruit juice 
(Dahan, Altman, 2004). This research paper will discuss the 
possible mechanisms behind this phenomenon and the 
components of grapefruit juice thought to cause the inter-
action. The effect and clinical relevance of grapefruit juice 
on two classes of cardiovascular medications, calcium 
channel antagonists and HMG-CoA reductase inhibitors, 
will be analyzed, and several ways of avoiding the interac-
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tions will be explored as well. 
Methods 
 Research was done using Touro College’s search 
engines such as ProQuest, and MEDLINE, and most fre-
quently, EBSCO. The method of research included evalu-
ating original studies and peer reviewed articles. Keywords 
such as “grapefruit juice”, “drug interaction”, and specific 
names of drugs were used. 
Mechanisms of Action 
 There are several possible mechanisms that have 
been suggested to explain the interaction. Since the inter-
action only takes place with drugs that are ingested orally, 
the mechanism must occur at some point during the diges-
tion process (Mertens-Talcott, et. al. 2006). 
Cytochrome P-450 3A4 
 Cytochrome P450 is a family of enzymes that is 
responsible for the breakdown and detoxification of, 
among other substances, steroids, environmental carcino-
gens, and drugs (Girennavar, et. al. 2007). Cytochrome P- 
450 3A4 (CYP3A4) specifically is the isoenzyme highly prev-
alent in the human digestive system, found in the small 
intestine and the liver. Drugs that are metabolized by 
CYP3A4 have low oral bioavailability, so only a small 
amount of the total that is ingested enters circulation. Be-
cause of this, larger doses are administered so that enough 
of the drug will be available to cause the desired effect. If 
CYP3A4 is inhibited, greater oral bioavailability results, and 
there is a possibility for undesired effects to occur (Bailey, 
Dresser, 2004). 
 Grapefruit juice has been shown to inhibit CYP3A4 
in in vitro studies. In one study, the enzyme was tested 
with 1%, 10%, and 25% concentrations of different species 
of grapefruit and pummel juices. Significant inhibition was 
observed, especially at concentrations of 10% and 25%. At 
those concentrations, inhibition ranged from 96.69% to 
99.88% (Girennavar, et. al. 2007). In another study that 
used human liver microsomes, inhibition was observed as 
well. (Seden, et. al. 2010) 
 Grapefruit juice has been proven to be an inhibitor 
of CYP3A4 in in vivo studies as well. Diminished CYP3A4 
enzyme presence, but not mRNA, has been observed after 
drinking just one 300 mL glass of grapefruit juice. The de-
creased levels indicate that the inhibition is not competi-
tive in nature.  (Bailey, Dresser, 2004). Additionally, an in-
vestigation that measured CYP3A4 levels after six days of 
drinking grapefruit juice recorded greatly decreased 
amounts of the enzyme but not of the CYP3A4 mRNA 
(Seden, et. al. 2010). Due to these observations, it can be 
assumed that grapefruit juice most likely does not inhibit 
production of the enzyme. Instead, the juice causes de-
struction of the enzyme through suicide or mechanism-
based inhibition. A component of grapefruit juice is 
thought to be converted to a reactive metabolite that 
bonds to CYP3A4 and causes inactivation (Bailey, Dresser, 
2004). 
 If this were the case, synthesis of new enzymes 
would be required for restoration of CYP3A4 activity, which 
explains the prolonged effect that grapefruit juice can 
have. Studies performed with felodipine to determine the 
length of time of the effect grapefruit juice support the 
theory. It was shown that the maximum effect can still be 
observed when the juice is ingested 4 hours before the 
drug is administered, and increased levels of felodipine 
were still recorded when there was a 24 hour interval be-
tween juice and drug intake (Bailey, Dresser, 2004). Recov-
ery times of 72 hours for nisoldipine (Bailey, Dresser, 2004) 
and 74 hours for midazolam (Mertens-Talcott, et. al. 2006) 
have been observed as well. 
 It is interesting to note that the effect of the inter-
action varies widely among individuals. Those with initial 
high CYP3A4 activity have been shown to have greater in-
hibition than those with naturally lower activity of the en-
zyme. Therefore, ingestion of grapefruit juice together 
with an affected drug by these individuals will cause a 
greater increase in drug concentration than would result in 
subjects with low CYP3A4 activity (Mertens-Talcott, et. al. 
2006). 
P-glycoprotein 
 P-glycoprotein is an ATP-dependent drug trans-
porter. It is an efflux pump located in the small intestine, 
liver, kidneys, and at the blood brain barrier. P-
glycoprotein decreases the bioavailability of many drugs by 
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Dresser, 2004). P-glycoprotein has many substrates, and a 
majority of them overlap with the substrates of CYP3A4. 
(Seden, et. al. 2010) 
 The inhibition of P-glycoprotein by grapefruit juice 
was first demonstrated by the increased uptake of vinblas-
tine into Caco-2 cells. Since vinblastine is a substrate of 
both CYP3A4 and P-glycoprotein, no definite conclusion 
could be drawn regarding the inhibition of P-glycoprotein 
(Mertens-Talcott, et. al. 2006). A study done using human 
renal proximal cells proved that grapefruit juice does in 
fact inhibit P-glycoprotein expression and activity (Romiti, 
et. al. 2004)  Another study investigated P-glycoprotein 
inhibition in Caco-2 cells as well, using colchicine as the 
probe. Grapefruit juice caused increased transport of col-
chicine into the cells. As is the case with vinblastine, colchi-
cine is both a CYP3A4 and a P-glycoprotein substrate, so 
the cause of the increased uptake can’t be credited solely 
to P-glycoprotein inhibition. The same study investigated 
colchicine permeability in the small intestine of rats in situ. 
It was found that grapefruit juice significantly increased the 
permeability of the drug (Dahan, Amidon, 2008). In an ad-
ditional investigation, rats were given talinolol, a substrate 
of P-glycoprotein that does undergo metabolization. Be-
cause of that, there is no potential for the inhibition of 
CYP3A4 to interfere with the results. When given together 
with grapefruit juice, concentrations of talinolol were in-
creased (Bailey, Dresser, 2004). 
 Although the in vitro studies demonstrate that 
there is a possible inhibition of P-glycoprotein by grapefruit 
juice, there have been difficulties in reproducing the 
effects in human trials (Seden, et. al. 2010). Digoxin is an-
other drug that is known to be an unmetabolized substrate 
of P-glycoprotein. The drug did not display a great change 
in bioavailability when administered with grapefruit juice 
as compared to water. But since digoxin has a high bioa-
vailability of 70-80%, it is not expected that inhibition of P-
glycoprotein would drastically change its concentration 
(Bailey, Dresser, 2004). 
 Although research has yet to produce clear proof, 
the above studies demonstrate that there is an interaction 
between grapefruit juice and P-glycoprotein. Further stud-
ies must be done to determine the extent of the inhibition 
and how significantly it affects grapefruit juice-drug inter-
actions. According to the current information, it seems to 
be that the interaction is mainly caused by inhibition of 
CYP3A4, and that inhibition of P-glycoprotein plays a small 
role as well. 
Components of Grapefruit juice Possibly Responsible 
 There are hundreds of chemical components pre-
sent in grapefruit juice. The amounts present in a specific 
juice depend on a variety of factors, including the genetic 
background of the plant, and the conditions during the 
growth, maturity, harvesting and processing of the fruit. 
Most of the constituents are present in other citrus fruits 
as well, but the amounts of the specific ones differ among 
the species. Since juices from numerous sources have dis-
played interactions with drugs, it seems that the compo-
nent or components that cause the interaction are always 
present. Two of the typically present substances, flavo-
noids and furanocoumarins have been presented as the 
most probable sources of the grapefruit juice effect (Fuhr, 
1998). 
Flavonoids 
 The flavonoid naringin is present in much higher 
levels in grapefruit juice than in other citrus fruit juices. 
Naringenin, the active metabolite of naringin, is known to 
be a strong inhibitor of CYP3A4. Several in vitro studies 
have shown that both naringin and naringenin are able to 
inhibit the metabolic process of the drugs tested (Fuhr, 
1998). Additionally, it has been demonstrated that 
naringenin has the ability to inhibit P-glycoprotein in hu-
man renal proximal cells (Romiti, et. al. 2004).   
 Although these trials seem promising, human trials 
have not gotten conclusive results. Studies that gave sub-
jects naringin in the form of capsules or in solution did not 
observe any significant increase in concentrations of the 
drugs that were tested. Furthermore, in a study in which 
naringin was removed from grapefruit juice, CYP3A4 activi-
ty was still inhibited (Fuhr, 1998). 
Furanocoumarins 
 Furanocoumarins are mainly found in the peels of 
grapefruit, but there are significant amounts present in the 
juice as well (Fuhr, 1998). The most abundant, bergamottin 




been identified as CYP3A4 inhibitors. Several in vitro stud-
ies have proven this. 
 The individual furanocoumarins have been isolated 
and tested in several studies. In one study, DHB, berga-
mottin, paradisin A, bergaptol and geranylcuomarin were 
tested for the extent of the inhibition that they caused. It 
was found that paradisin A was the strongest, followed by 
DHB, then bergamottin, then bergaptol, and finally geranly-
coumarin (Girennavar, et. al. 2007). Although DHB is not 
the strongest, it is the most abundant which is most proba-
bly why the inhibitory effect is generally attributed to its 
presence. In another study, the furanocoumarins were iso-
lated and tested as a whole to determine their overall in-
hibitory capacity. When all were combined, the inhibition 
was similar to that observed with whole grapefruit juice. 
Removing any one of the furanocoumarins from the mix-
ture decreased the inhibition, which presents the possibil-
ity that all of furanocoumarins play a role in the grapefruit 
juice effect (Dahan, Altman, 2004). 
 Further reinforcement of the role of furanocouma-
rins can be seen in studies that evaluated the effect of 
furanocoumarin-free grapefruit juice. In one study, most of 
the furanocoumarins were removed using Aspergillus ni-
ger, a strain of fungus. The altered juice was tested in vitro 
and found to have a reduced inhibitory effect (Myung, et. 
al. 2008). In another study, approximately 99% of the 
furanocoumarins were removed using food grade solvents 
and absorption resins. In vitro, the processed juice did 
cause some inhibition, but to a markedly lesser extent than 
did whole grapefruit juice. The same study performed a 
human trial, using felodipine as the probe. It was found 
that when compared to orange juice, the control, furano-
coumarin-free grapefruit juice had no great effect on the 
pharmacokinetics of the drug. This was the first study to 
show that the grapefruit juice effect can be credited com-
pletely to furanocoumarins (Paine, et. al. 2006). 
Drugs that Exhibit an Interaction 
 The drugs that are affected by grapefruit juice fol-
low a general trend. First of all, because the interaction 
occurs in the gastrointestinal tract, the medication must be 
ingested orally. Second, the drug in question must be ei-
ther metabolized by CYP3A4 or transported by P-
glycoprotein. Finally, since grapefruit juice increases bioa-
vailability, the drug must have a normally low bioavailabil-
ity (Bailey, Dresser, 2004). 
Dihydropyridine Calcium Channel Antagonists 
 Calcium channel antagonists are vasodilators that 
are used to treat hypertension and other cardiovascular 
disorders. Excessive vasodilation can result in headaches, 
swelling of the ankles, and facial flushing. These are not 
serious side effects, but they are unpleasant enough to 
cause patients to stop taking the medication, thus leaving 
their conditions untreated. The more serious side effects 
include severely low blood and pressure myocardial infarc-
tion (Bailey, Dresser, 2004). 
 Felodipine, the drug with which the grapefruit 
juice interaction was first observed, has been studied ex-
tensively. It has an absolute bioavailability of 15% (Bailey, 
Dresser, 2004). Over the course of these studies it has 
been determined that depending on the amount and tim-
ing of the ingestion of grapefruit juice, the concentrations 
of felodipine can increase to between double and triple 
the usual levels. Greater instances of adverse side effects 
were observed as well (Fuhr, 1998). 
 Nifedipine, another calcium channel antagonist 
with low oral bioavailability, has been shown to be affected 
by grapefruit juice as well.  In a single case study on a 50 
year old man, 500 ml of grapefruit juice caused nifedipine 
levels to more than double (Nakagawa, Gotu, 2010). Alt-
hough this was a single case study, and therefore no defi-
nite conclusions can be drawn, the results match those of 
larger studies. In another study, sixteen subjects drank 250 
ml of grapefruit juice. The observed result was much less 
dramatic than that of other studies, but there was an in-
crease in bioavailability. This can possibly be explained by 
the smaller amount of grapefruit juice administered. In 
most other studies, the amount ingested was between 400 
and 500 ml (Odou, et. al. 2005). Other drugs in this class 
that have displayed an interaction are nicardipine, nisodi-
pine, and nitrendipine. The average changes in concentra-
tion for the above range from 1.5 to four times the normal 
amount (Bailey, Dresser, 2004). 
 The final calcium channel antagonist, amlodipine, 
has a high oral bioavailability of between 64% and 80% 
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mottin, paradisin A, bergaptol and geranylcuomarin were 
tested for the extent of the inhibition that they caused. It 
was found that paradisin A was the strongest, followed by 
DHB, then bergamottin, then bergaptol, and finally geranly-
coumarin (Girennavar, et. al. 2007). Although DHB is not 
the strongest, it is the most abundant which is most proba-
bly why the inhibitory effect is generally attributed to its 
presence. In another study, the furanocoumarins were iso-
lated and tested as a whole to determine their overall in-
hibitory capacity. When all were combined, the inhibition 
was similar to that observed with whole grapefruit juice. 
Removing any one of the furanocoumarins from the mix-
ture decreased the inhibition, which presents the possibil-
ity that all of furanocoumarins play a role in the grapefruit 
juice effect (Dahan, Altman, 2004). 
 Further reinforcement of the role of furanocouma-
rins can be seen in studies that evaluated the effect of 
furanocoumarin-free grapefruit juice. In one study, most of 
the furanocoumarins were removed using Aspergillus ni-
ger, a strain of fungus. The altered juice was tested in vitro 
and found to have a reduced inhibitory effect (Myung, et. 
al. 2008). In another study, approximately 99% of the 
furanocoumarins were removed using food grade solvents 
and absorption resins. In vitro, the processed juice did 
cause some inhibition, but to a markedly lesser extent than 
did whole grapefruit juice. The same study performed a 
human trial, using felodipine as the probe. It was found 
that when compared to orange juice, the control, furano-
coumarin-free grapefruit juice had no great effect on the 
pharmacokinetics of the drug. This was the first study to 
show that the grapefruit juice effect can be credited com-
pletely to furanocoumarins (Paine, et. al. 2006). 
Drugs that Exhibit an Interaction 
 The drugs that are affected by grapefruit juice fol-
low a general trend. First of all, because the interaction 
occurs in the gastrointestinal tract, the medication must be 
ingested orally. Second, the drug in question must be ei-
ther metabolized by CYP3A4 or transported by P-
glycoprotein. Finally, since grapefruit juice increases bioa-
vailability, the drug must have a normally low bioavailabil-
ity (Bailey, Dresser, 2004). 
Dihydropyridine Calcium Channel Antagonists 
 Calcium channel antagonists are vasodilators that 
are used to treat hypertension and other cardiovascular 
disorders. Excessive vasodilation can result in headaches, 
swelling of the ankles, and facial flushing. These are not 
serious side effects, but they are unpleasant enough to 
cause patients to stop taking the medication, thus leaving 
their conditions untreated. The more serious side effects 
include severely low blood and pressure myocardial infarc-
tion (Bailey, Dresser, 2004). 
 Felodipine, the drug with which the grapefruit 
juice interaction was first observed, has been studied ex-
tensively. It has an absolute bioavailability of 15% (Bailey, 
Dresser, 2004). Over the course of these studies it has 
been determined that depending on the amount and tim-
ing of the ingestion of grapefruit juice, the concentrations 
of felodipine can increase to between double and triple 
the usual levels. Greater instances of adverse side effects 
were observed as well (Fuhr, 1998). 
 Nifedipine, another calcium channel antagonist 
with low oral bioavailability, has been shown to be affected 
by grapefruit juice as well.  In a single case study on a 50 
year old man, 500 ml of grapefruit juice caused nifedipine 
levels to more than double (Nakagawa, Gotu, 2010). Alt-
hough this was a single case study, and therefore no defi-
nite conclusions can be drawn, the results match those of 
larger studies. In another study, sixteen subjects drank 250 
ml of grapefruit juice. The observed result was much less 
dramatic than that of other studies, but there was an in-
crease in bioavailability. This can possibly be explained by 
the smaller amount of grapefruit juice administered. In 
most other studies, the amount ingested was between 400 
and 500 ml (Odou, et. al. 2005). Other drugs in this class 
that have displayed an interaction are nicardipine, nisodi-
pine, and nitrendipine. The average changes in concentra-
tion for the above range from 1.5 to four times the normal 
amount (Bailey, Dresser, 2004). 
 The final calcium channel antagonist, amlodipine, 
has a high oral bioavailability of between 64% and 80% 
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(Seden, et. al. 2010). Because of this, it is not expected to 
interact with grapefruit juice, and studies support this hy-
pothesis. In the same single case study discussed previous-
ly, grapefruit juice did not affect the plasma concentration 
of the drug (Nakagawa, Gotu 2010). In a study performed 
using twenty volunteers, 240 ml of grapefruit juice was 
ingested together with the amlodipine, and an additional 
200 ml was taken each day for 8 days following drug ad-
ministration. Bioavailability was not altered significantly 
(Vincent, et. al. 2000). 
HMG-CoA Reductase Inhibitors 
 HMG-CoA reductase inhibitors, commonly known 
as statins, are used to lower cholesterol. They have the 
potential to cause serious toxicity. Side effects range from 
diffuse myalgia, or muscle pain, to rhabdomyolysis, which 
is severe skeletal muscle degeneration. Acute renal failure 
is a possibility as well (Bailey, Dresser, 2004). 
 Simvastatin, lovastatin, and atorvastatin are all 
metabolized by CYP3A4 and therefore have low bioavaila-
bility. Simvastatin and lovastatin are inactive forms that are 
converted to their active acid forms by esterases. Before 
the conversion, they are extensively metabolized by 
CYP3A4, resulting in a bioavailability of approximately 5% 
(Bailey, Dresser, 2004). In one study, ten volunteers ingest-
ed 200 ml of grapefruit juice for two days before and then 
together with a dose of simvastatin. The average increase 
in concentration was 3.6 times greater than that observed 
with water (Lilja, et. al. 2004). In other studies that tested 
simvastatin and lovastatin, the average increase was 15-
fold the normal (Bailey, Dresser, 2004). 
 Atorvastatin has a bioavailability of 12%. In a study 
using eight subjects, grapefruit juice was ingested for three 
days before and concomitantly with atorvastatin. Juice was 
also administered 4 and 12 hours after drug intake. Con-
centrations increased between 1.5 and 1.7-fold (Ando, et. 
al. 2005). In another study that surveyed twenty subjects, 
grapefruit juice was consumed at regular intervals before, 
during and after administration of atorvastatin. The aver-
age increase that was observed was 83% (Fukazawa, et. al. 
2003). Finally, a much larger study was performed using 
130 subjects. Patients drank grapefruit daily for ninety days 
together with their medication, and there was a small but 
still statistically significant increase in concentrations 
(Reddy, et. al. 2011). 
 Pitavastatin, a synthetic statin, has a bioavailability 
of 60% (Ando, et. al. 2005). It is metabolized not by 
CYP3A4, but by CYP2C9, and to some extent by CYP2C8 
(Seden, et. al. 2010). In the study that surveyed the effects 
of grapefruit juice on atorvastatin in eight subjects, 
pitavastatin was tested as well. It was found that the juice 
only slightly increased concentrations of pitavastatin in the 
blood (Ando, et. al. 2005). 
 Like pitavastain, pravastatin is not metabolized by 
CYP3A4. Pravastatin was surveyed in the second study de-
scribed for atorvastatin that tested twenty subjects. No 
significant effects were recorded (Fukazawa, et. al. 2003). 
Two other statins, fluvastatin and rosuvastatin, have not 
yet been tested (Seden, et. al. 2010). But fluvastatin is a 
CYP2C9 substrate, and rosuvastatin appears not to be a 
substrate of either CYP3A4 or P-glycoprotein, so no inter-
actions are predicted (Bailey, Dresser, 2004). 
How to Avoid the Interaction 
 The simplest way to avoid the interaction would be 
to abstain from drinking grapefruit juice while undergoing 
treatment with a drug that is known to, or has been pre-
dicted to, interact with grapefruit juice. If the patient has 
no interest in giving up the juice, the next best solution 
would be to select one of the drugs that have been proven 
to have no interaction with the juice. However, if that spe-
cific drug is required, and changing to a non-interacting 
medication is impossible, there are several methods that 
might limit the possibility of an interaction occurring. 
 As it has been proven that furanocoumarins are 
the cause of the grapefruit juice-drug interaction, the ideal 
way to minimize the possibility of an interaction occurring 
is to limit exposure to furanocoumarins. Below are several 
possible ways in which the levels of furanocoumarins can 
be reduced. 
Harvest Factors and Different Species of Grapefruit 
 It has been proven that the maturity, location, pro-
cessing, and storage of grapefruits and grapefruit juice 
affects the levels of furanocoumarins present in the final 




produced in times of stress so there are many factors that 
affect their levels. It was found that furanocoumarin levels 
are highest at the beginning of season, and that they de-
crease throughout the season. In evaluating location, it 
was discovered that in general, grapefruits grown in Florida 
and California had higher levels than grapefruits grown in 
Texas. Hand squeezing versus commercial processing tests 
revealed that levels were higher in hand squeezed juice. 
Post-harvest, furanocoumarin levels were lowered when 
stored at both 24 and 9°C. Finally, levels were evaluated in 
processed juice stored in three different types of contain-
ers: cans, cardboard bottles, and cartons. All displayed a 
decrease in levels over time, but the cartons contained the 
highest levels of furanocoumarins (Girennavar, et. al. 
2008). Based on these findings, those who would like to 
drink grapefruit juice and minimize the possibility for an 
interaction should choose commercially processed juice 
stored in cans or bottles, and made from organic grape-
fruits grown in Texas that were harvested late in the sea-
son. 
Furanocoumarin-Free Grapefruit Juice 
 Furanocoumarins have been extracted from grape-
fruit juice for studies, but commercial furanocoumarin-free 
juice has not been developed. Based on the studies, there 
are two possible ways to extract them. In one study, the 
fungi Aspergillus niger was incubated with grapefruit juice. 
The fungus was able to absorb most of the non-polar 
furanocoumarins, but not the polar ones, and not the fla-
vonoids. The juice was then tested on CYP3A4, and it was 
found that inhibition of the enzyme was significantly re-
duced. This method still needs further development 
though, because the strain of fungus that was used could 
produce toxins. For the removal of furanocoumarins from 
grapefruit juice by fungus to become possible commercial-
ly, a method employing food-grade, edible fungi must be 
developed (Myung, et. al. 2008). In another study, furano-
coumarin-free grapefruit juice was created using food-
grade solvents and absorption resins. 99% of the furano-
coumarins were able to be removed. When tested in a hu-
man trial, the juice had no effect on the concentrations of 
felodipine (Paine, et. al. 2006). 
 
Conclusion 
 As seen in the above studies, grapefruit juice has 
the potential to interact with many drugs. Any medication 
that is either a substrate of CYP3A4 or transported by P-
glycoprotein can possibly be affected when taken together 
with grapefruit juice.  The components in the juice that are 
responsible for the interaction are the furanocoumarins, 
which bind to and inactivate CYP3A4 and P-glycoprotein. 
Avoidance of the interaction is best accomplished by not 
drinking grapefruit juice, or selecting a drug that is known 
not to interact. If such actions are not possible, juice that 
was processed so as to minimize furanocoumarins might 
be a possibility, and there is a chance that furanocoumarin-
free grapefruit juice will be developed sometime in the 
future. 
 Since there are so many drugs that have the possi-
bility of interaction, it is important to simply be aware of 
this phenomenon. Patients must know to let their doctors 
know if they drink grapefruit juice habitually and to ask if 
any medications that they are on can interact. Unless it has 
been proved that there is no possibility of a reaction, any 
drug that might interact based on the method in which it’s 
metabolized should be treated as if it is privy to the grape-
fruit juice-drug interaction. 
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(Seden, et. al. 2010). Because of this, it is not expected to 
interact with grapefruit juice, and studies support this hy-
pothesis. In the same single case study discussed previous-
ly, grapefruit juice did not affect the plasma concentration 
of the drug (Nakagawa, Gotu 2010). In a study performed 
using twenty volunteers, 240 ml of grapefruit juice was 
ingested together with the amlodipine, and an additional 
200 ml was taken each day for 8 days following drug ad-
ministration. Bioavailability was not altered significantly 
(Vincent, et. al. 2000). 
HMG-CoA Reductase Inhibitors 
 HMG-CoA reductase inhibitors, commonly known 
as statins, are used to lower cholesterol. They have the 
potential to cause serious toxicity. Side effects range from 
diffuse myalgia, or muscle pain, to rhabdomyolysis, which 
is severe skeletal muscle degeneration. Acute renal failure 
is a possibility as well (Bailey, Dresser, 2004). 
 Simvastatin, lovastatin, and atorvastatin are all 
metabolized by CYP3A4 and therefore have low bioavaila-
bility. Simvastatin and lovastatin are inactive forms that are 
converted to their active acid forms by esterases. Before 
the conversion, they are extensively metabolized by 
CYP3A4, resulting in a bioavailability of approximately 5% 
(Bailey, Dresser, 2004). In one study, ten volunteers ingest-
ed 200 ml of grapefruit juice for two days before and then 
together with a dose of simvastatin. The average increase 
in concentration was 3.6 times greater than that observed 
with water (Lilja, et. al. 2004). In other studies that tested 
simvastatin and lovastatin, the average increase was 15-
fold the normal (Bailey, Dresser, 2004). 
 Atorvastatin has a bioavailability of 12%. In a study 
using eight subjects, grapefruit juice was ingested for three 
days before and concomitantly with atorvastatin. Juice was 
also administered 4 and 12 hours after drug intake. Con-
centrations increased between 1.5 and 1.7-fold (Ando, et. 
al. 2005). In another study that surveyed twenty subjects, 
grapefruit juice was consumed at regular intervals before, 
during and after administration of atorvastatin. The aver-
age increase that was observed was 83% (Fukazawa, et. al. 
2003). Finally, a much larger study was performed using 
130 subjects. Patients drank grapefruit daily for ninety days 
together with their medication, and there was a small but 
still statistically significant increase in concentrations 
(Reddy, et. al. 2011). 
 Pitavastatin, a synthetic statin, has a bioavailability 
of 60% (Ando, et. al. 2005). It is metabolized not by 
CYP3A4, but by CYP2C9, and to some extent by CYP2C8 
(Seden, et. al. 2010). In the study that surveyed the effects 
of grapefruit juice on atorvastatin in eight subjects, 
pitavastatin was tested as well. It was found that the juice 
only slightly increased concentrations of pitavastatin in the 
blood (Ando, et. al. 2005). 
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CYP3A4. Pravastatin was surveyed in the second study de-
scribed for atorvastatin that tested twenty subjects. No 
significant effects were recorded (Fukazawa, et. al. 2003). 
Two other statins, fluvastatin and rosuvastatin, have not 
yet been tested (Seden, et. al. 2010). But fluvastatin is a 
CYP2C9 substrate, and rosuvastatin appears not to be a 
substrate of either CYP3A4 or P-glycoprotein, so no inter-
actions are predicted (Bailey, Dresser, 2004). 
How to Avoid the Interaction 
 The simplest way to avoid the interaction would be 
to abstain from drinking grapefruit juice while undergoing 
treatment with a drug that is known to, or has been pre-
dicted to, interact with grapefruit juice. If the patient has 
no interest in giving up the juice, the next best solution 
would be to select one of the drugs that have been proven 
to have no interaction with the juice. However, if that spe-
cific drug is required, and changing to a non-interacting 
medication is impossible, there are several methods that 
might limit the possibility of an interaction occurring. 
 As it has been proven that furanocoumarins are 
the cause of the grapefruit juice-drug interaction, the ideal 
way to minimize the possibility of an interaction occurring 
is to limit exposure to furanocoumarins. Below are several 
possible ways in which the levels of furanocoumarins can 
be reduced. 
Harvest Factors and Different Species of Grapefruit 
 It has been proven that the maturity, location, pro-
cessing, and storage of grapefruits and grapefruit juice 
affects the levels of furanocoumarins present in the final 




produced in times of stress so there are many factors that 
affect their levels. It was found that furanocoumarin levels 
are highest at the beginning of season, and that they de-
crease throughout the season. In evaluating location, it 
was discovered that in general, grapefruits grown in Florida 
and California had higher levels than grapefruits grown in 
Texas. Hand squeezing versus commercial processing tests 
revealed that levels were higher in hand squeezed juice. 
Post-harvest, furanocoumarin levels were lowered when 
stored at both 24 and 9°C. Finally, levels were evaluated in 
processed juice stored in three different types of contain-
ers: cans, cardboard bottles, and cartons. All displayed a 
decrease in levels over time, but the cartons contained the 
highest levels of furanocoumarins (Girennavar, et. al. 
2008). Based on these findings, those who would like to 
drink grapefruit juice and minimize the possibility for an 
interaction should choose commercially processed juice 
stored in cans or bottles, and made from organic grape-
fruits grown in Texas that were harvested late in the sea-
son. 
Furanocoumarin-Free Grapefruit Juice 
 Furanocoumarins have been extracted from grape-
fruit juice for studies, but commercial furanocoumarin-free 
juice has not been developed. Based on the studies, there 
are two possible ways to extract them. In one study, the 
fungi Aspergillus niger was incubated with grapefruit juice. 
The fungus was able to absorb most of the non-polar 
furanocoumarins, but not the polar ones, and not the fla-
vonoids. The juice was then tested on CYP3A4, and it was 
found that inhibition of the enzyme was significantly re-
duced. This method still needs further development 
though, because the strain of fungus that was used could 
produce toxins. For the removal of furanocoumarins from 
grapefruit juice by fungus to become possible commercial-
ly, a method employing food-grade, edible fungi must be 
developed (Myung, et. al. 2008). In another study, furano-
coumarin-free grapefruit juice was created using food-
grade solvents and absorption resins. 99% of the furano-
coumarins were able to be removed. When tested in a hu-
man trial, the juice had no effect on the concentrations of 
felodipine (Paine, et. al. 2006). 
 
Conclusion 
 As seen in the above studies, grapefruit juice has 
the potential to interact with many drugs. Any medication 
that is either a substrate of CYP3A4 or transported by P-
glycoprotein can possibly be affected when taken together 
with grapefruit juice.  The components in the juice that are 
responsible for the interaction are the furanocoumarins, 
which bind to and inactivate CYP3A4 and P-glycoprotein. 
Avoidance of the interaction is best accomplished by not 
drinking grapefruit juice, or selecting a drug that is known 
not to interact. If such actions are not possible, juice that 
was processed so as to minimize furanocoumarins might 
be a possibility, and there is a chance that furanocoumarin-
free grapefruit juice will be developed sometime in the 
future. 
 Since there are so many drugs that have the possi-
bility of interaction, it is important to simply be aware of 
this phenomenon. Patients must know to let their doctors 
know if they drink grapefruit juice habitually and to ask if 
any medications that they are on can interact. Unless it has 
been proved that there is no possibility of a reaction, any 
drug that might interact based on the method in which it’s 
metabolized should be treated as if it is privy to the grape-
fruit juice-drug interaction. 
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 The Center for Disease Control   claims that fluori-
dating the water is one of the greatest achievements in the 
twentieth century in terms of preventing disease (CDC, 
1999). In fact, it is estimated that by 2005 60% of the coun-
try already had access to fluoridated water (Kauffman, 
2005). The supposed benefit is that fluoride help reduce 
dental caries. While the exact mechanism is not fully un-
derstood there is a prevailing theory as to why it does 
work. Indeed, it has been noticed that since the induction 
of fluoride to water supplies worldwide there has been a 
downward trend in cavities (Jones, et al. 2005).  However, 
fluoride use is synonymous with fluorosis, the discoloration 
of teeth. While this isn’t a significant health risk, it is un-
sightly and can make the child feel uncomfortable. Cur-
rently, there is limited treatment available for fluorotic 
teeth ranging from bleaching to crown restoration 
(Sherwood, 2010). It remains to be seen if fluoridation of 
the water is the optimal method for delivering fluoride to 
our children. In fact, given the widespread dissemination of 
fluoridated products there are other methods to ensure 
that children have adequate fluoride intake.  By examining 
the data and studying trends   associated with fluoride use 
both in water and as a supplement, scientists can use the 
resulting information to suggest necessary changes in the 
child’s fluoride intake and modify their diet to achieve the 
maximized benefit from fluoride intake. 
Method 
 In conducting this research Touro’s online library, 
and the publications it is affiliated with, specifically Pub-
med were searched. In addition, Google Scholar and online 
search engines as well as the resources available at the 
public library and its computer access to various online 
journals were utilized. 
Discussion 
Dental Caries 
 Dental caries, is the most common infectious dis-
ease affecting children, both in developed and third world 
countries (Colak, et. Al. 2013). They are formed primarily in 
pits and fissure where bacteria cling and metabolize sug-
ars . The tooth is composed of two sections , the crown 
which is the exposed section, and the root which goes 
down and is embedded in the bone. The outermost layer 
of the crown is enamel which is comprised primarily of 
hard tightly packed rods of hydroxyapatite (Ca10(OH)2PO4)
6) . The saliva in the mouth greatly aids in biofilm formation 
and allows various bacteria to colonize the tooth (Talaro, 
2009). In fact, there is a diverse population of bacteria that 
inhabit the mouth estimated to be up to 300 different spe-
cies (Loesche, 1986). When carbohydrates are consumed 
and broken down in the mouth by salivary enzymes into 
sugar components, oral bacteria will metabolize them and 
produce acid as a by-product. Current research suggests 
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